Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Richard Furie; Munther Khamashta; Joan T. Merrill; Victoria P. Werth; Kenneth Kalunian; Philip Brohawn; Gabor G. Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo; for the CD1013 Study Investigators

doi:10.1002/art.39962

Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Richard Furie, Munther Khamashta, Joan T. Merrill, Victoria P. Werth, Kenneth Kalunian, Philip Brohawn, Gabor G. Illei, Jorn Drappa, Liangwei Wang, Stephen Yoo, for the CD1013 Study Investigators

Women & Children's Health

Research output: Contribution to journal › Article › peer-review

622 Citations (Scopus)

280 Downloads (Pure)

Abstract

Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). Methods Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (

Original language	English
Pages (from-to)	376-386
Number of pages	11
Journal	Arthritis and Rheumatology
Volume	69
Issue number	2
Early online date	28 Jan 2017
DOIs	https://doi.org/10.1002/art.39962
Publication status	Published - Feb 2017

Access to Document

10.1002/art.39962Licence: CC BY-NC-ND

Anifrolumab, an Anti–Interferon-a_FURIE_Firstonline28January2017_GOLD VoR (CC-BY-NC-ND)Final published version, 463 KBLicence: CC BY-NC-ND

Cite this

@article{e0faec2ac79e4da4933fafa7d8b3892c,

title = "Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus",

abstract = "Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). Methods Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (",

author = "Richard Furie and Munther Khamashta and Merrill, {Joan T.} and Werth, {Victoria P.} and Kenneth Kalunian and Philip Brohawn and Illei, {Gabor G.} and Jorn Drappa and Liangwei Wang and Stephen Yoo and Investigators, {for the CD1013 Study}",

year = "2017",

month = feb,

doi = "10.1002/art.39962",

language = "English",

volume = "69",

pages = "376--386",

journal = "Arthritis and Rheumatology",

issn = "2326-5205",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

AU - Furie, Richard

AU - Khamashta, Munther

AU - Merrill, Joan T.

AU - Werth, Victoria P.

AU - Kalunian, Kenneth

AU - Brohawn, Philip

AU - Illei, Gabor G.

AU - Drappa, Jorn

AU - Wang, Liangwei

AU - Yoo, Stephen

AU - Investigators, for the CD1013 Study

PY - 2017/2

Y1 - 2017/2

N2 - Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). Methods Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (

AB - Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). Methods Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (

U2 - 10.1002/art.39962

DO - 10.1002/art.39962

M3 - Article

SN - 2326-5205

VL - 69

SP - 376

EP - 386

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

IS - 2

ER -

Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Abstract

Access to Document

Fingerprint

Cite this